We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials
Effectiveness of Diabetes and Weight-Loss Drugs in Overweight or Diabetic Teenagers: A Review of Clinical Trials
AI simplified
Abstract
A total of 1,262 participants were included in the meta-analysis of glucagon-like peptide-1 receptor agonists (GLP-1RAs).
- GLP-1RAs resulted in a significant reduction in glycosylated hemoglobin A1c (HbA1c) by -0.34% compared to the control group (p<0.001).
- No significant difference in fasting plasma glucose was observed between the GLP-1RAs and control groups (RD=-2.07 mg/dL, p=0.065).
- Participants receiving GLP-1RAs experienced a more significant decline in body weight (RD=-4.28 kg, p=0.002) and body mass index (BMI) (RD=-1.63 kg/m, p=0.002) compared to the control group.
- The liraglutide group showed a significant weight reduction of -2.31 kg (p=0.038), while exenatide resulted in a weight loss of -2.70 kg (p<0.001).
- In terms of BMI, exenatide demonstrated a significant reduction (RD=-1.14 kg/m, p<0.001), while liraglutide did not show a significant difference in BMI reduction (RD=-0.81 kg/m, p=0.260).
AI simplified